Table 1.

Characteristics of the study cohort, antibody titers, and time intervals between vaccine doses and testing.

Variable
Gender
Male	12 (32.4)	N (%)
Female	25 (67.6)	N (%)
Age	45.5 ± 12.5	Mean ± SD (years)
<50	19 (51.4)	N (%)
≥50	18 (48.6)	N (%)
Antibody titer after the 2nd dose (Test1)	652.2 ± 450.7	Mean ± SD (U/mL)
Antibody titer after the 3rd dose (Test2)	17,446.8 ± 7323.7	Mean ± SD (U/mL)
Interval 1st–2nd dose	22 ± 5	Mean ± SD (days)
Interval 1st–3rd dose	307 ± 31	Mean ± SD (days)
Interval 2nd–3rd dose	284 ± 35	Mean ± SD (days)
Interval 2nd dose–Test1	262 ± 33	Mean ± SD (days)
Interval Test1–3rd dose	22 ± 17	Mean ± SD (days)
Interval 3rd dose–Test2	35 ± 17	Mean ± SD (days)